G. Karam, J. Chastre, M. H. Wilcox, and J. Vincent, Antibiotic strategies in the era of multidrug resistance, Crit Care, vol.20, p.136, 2016.

J. Vincent, M. Bassetti, B. François, G. Karam, J. Chastre et al., Advances in antibiotic therapy in the critically ill, Crit Care, vol.20, 2016.

A. Brasseur, M. Hites, S. Roisin, F. Cotton, J. Vincent et al., A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study, J Antimicrob Chemother, vol.71, pp.1386-94, 2016.

R. Gálvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero et al., Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity, Int J Antimicrob Agents, vol.38, pp.146-51, 2011.

W. Duszynska, F. S. Taccone, M. Hurkacz, B. Kowalska-krochmal, A. Wiela-hoje?ska et al., Therapeutic drug monitoring of amikacin in septic patients, Crit Care, vol.17, p.165, 2013.

B. Layeux, F. S. Taccone, D. Fagnoul, J. Vincent, and F. Jacobs, Amikacin Monotherapy for Sepsis Caused by Panresistant Pseudomonas aeruginosa, Antimicrob Agents Chemother, vol.54, pp.4939-4980, 2010.

F. S. Taccone, Optimising amikacin regimens in septic patients, Int J Antimicrob Agents, vol.39, pp.264-269, 2012.

F. S. Taccone, P. Laterre, H. Spapen, T. Dugernier, I. Delattre et al., Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock, Crit Care, vol.14, p.53, 2010.

R. D. Moore, C. R. Smith, and P. S. Lietman, The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia, J Infect Dis, vol.149, pp.443-451, 1984.

. Eucast and . European, Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, 2016.

C. Roger, B. Nucci, B. Louart, A. Friggeri, H. Knani et al., Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis, J Antimicrob Chemother, vol.71, pp.208-220, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01912185

M. J. Rybak, B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner et al., Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity, Antimicrob Agents Chemother, vol.43, pp.1549-55, 1999.

E. M. Mazzaferro and R. B. Ford, Section I -Emergency Care, pp.1-294, 2012.

M. L. Wellman, S. P. Dibartola, and C. W. Kohn, Chapter 1 -Applied Physiology of Body Fluids in Dogs and Cats. Fluid Electrolyte Acid-Base Disord, Small Anim. Pract. Fourth Ed, pp.2-25, 2012.

M. Nawaz and B. H. Shah, Renal clearance of endogenous creatinine and urea in sheep during summer and winter, Res Vet Sci, vol.36, pp.220-224, 1984.

. Ansm, Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, nétilmicine, amikacine, 2011.

F. S. Taccone, D. De-backer, P. Laterre, H. Spapen, T. Dugernier et al., Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy, Int J Antimicrob Agents, vol.37, pp.531-536, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00690059

M. Neely, M. Van-guilder, W. Yamada, A. Schumitzky, and R. Jelliffe, Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R, Ther Drug Monit, vol.34, pp.467-76, 2012.

M. Bergstrand, A. C. Hooker, J. E. Wallin, and M. O. Karlsson, Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, vol.13, pp.143-51, 2011.

S. Carli, C. Montesissa, O. Sonzogni, M. Madonna, and A. Said-faqi, Comparative pharmacokinetics of amikacin sulphate in calves and sheep, Res Vet Sci, vol.48, pp.231-235, 1990.

A. Haritova and L. Lashev, Pharmacokinetics of amikacin in lactating sheep, Vet Res Commun, vol.28, pp.429-464, 2004.

D. M. D'arcy, C. E. Gowing, C. M. Donnelly, M. B. Corrigan, and O. I. , An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration, BMC Pharmacol Toxicol, vol.13, p.14, 2012.

D. K. Armstrong, T. Hodgman, J. A. Visconti, T. E. Reilley, W. L. Garner et al., Hemodialysis of amikacin in critically ill patients, Crit Care Med, vol.16, pp.517-537, 1988.

Q. Tian, C. D. Gomersall, M. Ip, P. E. Tan, G. M. Joynt et al., Adsorption of Amikacin, a Significant Mechanism of Elimination by Hemofiltration, Antimicrob Agents Chemother, vol.52, pp.1009-1022, 2008.

P. B. Kerr, A. Argilés, J. Flavier, B. Canaud, and C. M. Mion, Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study, Kidney Int, vol.41, pp.1035-1075, 1992.

S. W. Lam and S. R. Bauer, Amikacin Pharmacokinetics During Continuous Veno-Venous Hemodialysis, Infect Dis Ther, vol.2, pp.217-243, 2013.

B. Misset, J. Timsit, S. Chevret, B. Renaud, F. Tamion et al., A randomized crossover comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure, Intensive Care Med, vol.22, pp.742-748, 1996.

R. D. Swartz, J. M. Messana, S. Orzol, and F. K. Port, Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure, Am J Kidney Dis, vol.34, pp.424-456, 1999.

I. Nistor, S. C. Palmer, J. C. Craig, V. Saglimbene, M. Vecchio et al., Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease

, Cochrane Database Syst Rev, vol.5, p.6258, 2015.

K. Chater and J. A. Kellum, Continuous vs. intermittent hemodialysis: with which spin will my patient win?, Crit Care, vol.11, p.313, 2007.

D. E. Uehlinger, S. M. Jakob, P. Ferrari, M. Eichelberger, U. Huynh-do et al., Comparison of continuous and intermittent renal replacement therapy for acute renal failure, Nephrol Dial Transplant, vol.20, pp.1630-1637, 2005.

G. L. Drusano, P. G. Ambrose, S. M. Bhavnani, J. S. Bertino, A. N. Nafziger et al., Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally, Clin Infect Dis, vol.45, pp.753-60, 2007.

J. S. Bertino, L. A. Booker, P. A. Franck, P. L. Jenkins, K. R. Franck et al., Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring, J Infect Dis, vol.167, pp.173-182, 1993.

R. Gauzit, Actualités en antibiothérapie -Aminosides toujours et encore: bon usage et suivi thérapeutique, Réanimation, vol.20, pp.290-298, 2010.

C. A. Palm, G. Segev, . Leroy-b-e, . Kowalkowski, and K. Kanakubo,

, Urinary Neutrophil Gelatinase-associated Lipocalin as a Marker for Identification of Acute Kidney Injury and Recovery in Dogs with Gentamicin-induced Nephrotoxicity, J Vet Intern Med, vol.30, pp.200-205, 2016.

M. A. Aziz and S. S. Carlyle, Cardiovascular and Respiratory Effects of Xylazine in Sheep, Zentralblatt Für Veterinärmedizin Reihe A, vol.25, pp.173-80, 1978.

I. A. Gómez-de-segura, F. J. Tendillo, A. Mascías, M. Santos, J. L. Castillo-olivares et al., Actions of xylazine in young swine, Am J Vet Res, vol.58, pp.99-102, 1997.

. Dalen-r-van and T. B. Vree, Pharmacokinetics of antibiotics in critically ill patients, Intensive Care Med, vol.16, pp.235-243, 1990.

S. E. Aiello, The Merck Veterinary Manual. 11th Edition. Merck publishing, 2016.